United Kingdom (UK) Oncology Market Outlook to 2033: Colorectal Cancer Screening Tests, EGFR Tests, KRAS Tests and Others

All the vital news, analysis, and commentary curated by our industry experts.

$4995

Buy Report

Published: June 23, 2025 Report Code: GDME25626CCDB-ST

Report Overview
Key Players
Table of Contents
Table
Figures

GlobalData’s “United Kingdom Oncology Market Outlook to 2033” is a comprehensive databook report, covering key market data on the United Kingdom Oncology market. The databook report provides value (USD), volume (units) and average prices (USD) within market segments – Colorectal Cancer Screening Tests, EGFR Tests, KRAS Tests, HER2 Tests, BRCA Tests, ALK Tests, BRAF Tests, BCR-ABL Tests and PD-L1 Tests

The United Kingdom Oncology Market report provides key information and data on –
• Annualized market revenues (USD), volume (units) and average prices (USD) data for each of the market segments. Data is provided from 2018 to 2033.
• 2024 company share data for Oncology Market.
• Global corporate-level profiles of key companies operating within the United Kingdom Oncology Market. Based on the availability of data for the particular category and country, information related to pipeline products, news and deals is also available in the report.

Scope

United Kingdom Oncology is segmented as follows – _x000D_

• Colorectal Cancer Screening Tests_x000D_

• EGFR Tests_x000D_

• KRAS Tests_x000D_

• HER2 Tests_x000D_

• BRCA Tests_x000D_

• ALK Tests_x000D_

• BRAF Tests_x000D_

• BCR-ABL Tests_x000D_

• PD-L1 Tests

Reasons to Buy

The United Kingdom Oncology Market report helps you to develop –

• Business strategies by identifying the key market segments poised for strong growth in the future.

• Market-entry and market expansion strategies.

• Design competition strategies by identifying who-stands-where in the market.

• Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.

• Understand the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.

Abbott Laboratories

|1 Table of Contents 3

|1.1 List of Tables 6

|1.2 List of Figures 6

2 Introduction 7

2.1 What Is This Report About? 7

2.2 Oncology Market Segmentation 7

2.3 Definitions of Markets Covered in the Report 9

3 Oncology Market, United Kingdom 16

3.1 Oncology Market, United Kingdom, Revenue ($m), 2018-2033 16

3.1.1 ALK Tests Market, United Kingdom, Revenue ($m), by Segment, 2018-2033 19

3.1.2 BCR-ABL Tests Market, United Kingdom, Revenue ($m), by Segment, 2018-2033 21

3.1.3 BRAF Tests Market, United Kingdom, Revenue ($m), by Segment, 2018-2033 23

3.1.4 BRCA Tests Market, United Kingdom, Revenue ($m), by Segment, 2018-2033 25

3.1.5 Colorectal Cancer Screening Tests Market, United Kingdom, Revenue ($m), by Segment, 2018-2033 27

3.1.6 EGFR Tests Market, United Kingdom, Revenue ($m), by Segment, 2018-2033 29

3.1.7 HER2 Tests Market, United Kingdom, Revenue ($m), by Segment, 2018-2033 31

3.1.8 KRAS Tests Market, United Kingdom, Revenue ($m), by Segment, 2018-2033 33

3.2 Oncology Market, United Kingdom, Volume (Units), 2018-2033 35

3.2.1 ALK Tests Market, United Kingdom, Volume (Units), by Segment, 2018-2033 38

3.2.2 BCR-ABL Tests Market, United Kingdom, Volume (Units), by Segment, 2018-2033 40

3.2.3 BRAF Tests Market, United Kingdom, Volume (Units), by Segment, 2018-2033 42

3.2.4 BRCA Tests Market, United Kingdom, Volume (Units), by Segment, 2018-2033 44

3.2.5 Colorectal Cancer Screening Tests Market, United Kingdom, Volume (Units), by Segment, 2018-2033 46

3.2.6 EGFR Tests Market, United Kingdom, Volume (Units), by Segment, 2018-2033 49

3.2.7 HER2 Tests Market, United Kingdom, Volume (Units), by Segment, 2018-2033 51

3.2.8 KRAS Tests Market, United Kingdom, Volume (Units), by Segment, 2018-2033 53

3.3 Oncology Market, United Kingdom, Average Price ($) , 2018-2033 55

3.4 Oncology Market, United Kingdom, Company Share by Revenue ($m), 2024 59

4 Overview of Key Companies in United Kingdom, Oncology Market 61

4.1 F. Hoffmann-La Roche Ltd 61

4.1.1 Company Overview 61

4.2 Resonac Corporation 61

4.2.1 Company Overview 61

4.3 Eiken Chemical Co Ltd 61

4.3.1 Company Overview 61

4.4 Agilent Technologies Inc 61

4.4.1 Company Overview 61

4.5 Danaher Corp 62

4.5.1 Company Overview 62

4.6 Hemosure Inc 62

4.6.1 Company Overview 62

4.7 Abbott Laboratories 62

4.7.1 Company Overview 62

4.8 Quidelortho Corp 62

4.8.1 Company Overview 62

4.9 Alfresa Pharma Corp 62

4.9.1 Company Overview 62

4.10 SENTINEL CH SpA 63

4.9.1 Company Overview 63

5 Oncology Market Pipeline Products 64

6 Financial Deals Landscape 128

6.1 Partnerships 128

6.1.1 EDX Medical Enters into Distribution Agreement with miRdetect 128

6.1.2 Owkin Enters into Co-Development Agreement with AstraZeneca 129

6.1.3 A. Menarini Diagnostics Enters into Distribution Agreement with Nucleix 131

6.2 Venture Financing 133

6.2.1 Vidac Pharma Holding Raises Approximately USD0.64 Million in Venture Financing 133

7 Recent Developments 135

7.1 Corporate Communications 135

7.1.1 Feb 11, 2025: UK-backed AI Companies to Transform British Cancer Care and Spark New Drug Breakthroughs 135

7.1.2 Oct 09, 2024: New Hub to Develop Advanced Cancer Imaging Techniques 136

7.1.3 Oct 07, 2024: UK Government greenlights £146m tech package to tackle cancer 137

7.1.4 Sep 09, 2024: NIHR Announces New Funding Opportunities for Novel Brain Tumour Research Launched 137

7.1.5 Jun 12, 2024: MaxCyte Announces Result of AGM 138

7.2 Financial Announcements 139

7.2.1 Aug 06, 2024: MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance 139

7.2.2 Jun 13, 2024: NetScientific Releases Preliminary Results for Year Ended December 31, 2023 140

7.3 Government and Public Interest 142

7.3.1 Apr 23, 2025: CRUK Funding for Research Into Earlier Detection of Relapse in People With Multiple Myeloma 142

7.3.2 Apr 14, 2025: Tackling Vulnerabilities in the Supply Chain of Radiopharmaceuticals in the EU 142

7.3.3 Nov 05, 2024: UK to Create World-First ‘Early Warning System’ for Pandemics 142

7.4 Legal And Regulatory 144

7.4.1 Dec 04, 2024: MHRA trials five innovative AI Technologies as Part of Pilot Scheme to Change Regulatory Approach 144

7.5 Other Significant Developments 146

7.5.1 Apr 24, 2025: Stellaromics Announces First Deployment of Pyxa Platform in Europe 146

7.5.2 Feb 11, 2025: Alcidion Receives Contract With Hywel Dda University Health Board in Wales 146

7.5.3 Dec 17, 2024: Diaceutics Wins New $5.1m Contract 146

7.5.4 Nov 29, 2024: NHS calls for women to attend routine cervical screenings 147

7.5.5 Oct 19, 2024: Institute of Cancer Research : £1.5m AI and Genetics Project to Find Men with Deadliest Prostate Cancers Early 147

7.5.6 Oct 09, 2024: Proteotype Awarded £1.5 Million Grant to Advance Early Cancer Detection with Innovative Enlighten Test 148

7.5.7 Sep 02, 2024: EDX Medical partners with Caris Life Sciences for molecular profiling 149

7.5.8 Aug 20, 2024: Dr.Tanya Stoyanova Receives Grant to Develop New Radiopharmaceuticals for Cancer 150

7.5.9 Jun 26, 2024: EDX Medical to Market Pioneering Cancer Drugs Response Assay in UK and Nordics 150

7.5.10 Jun 11, 2024: Uk’s First Robotic Genome Testing Facility for Cancer Patients Launches 151

7.6 Product News 152

7.6.1 Mar 24, 2025: Research Shows Importance of Genomic Testing and Targeted Therapies for Advanced Cancers 152

7.6.2 Feb 03, 2025: New Screening Device Shows Promise for Early Lung Cancer Detection 152

7.6.3 Jan 17, 2025: Genetic Testing for Lynch Syndrome Prevents Cancers Being Missed 153

7.6.4 Jan 14, 2025: Panakeia Announces Launch of PANProfiler Colon 154

7.6.5 Jan 09, 2025: New ‘Explant’ Technique Predicts a Tumour’s Responsiveness to Breast Cancer Treatment 154

7.6.6 Dec 18, 2024: Clarity Announces Expansion of Pipeline With Novel Optimised FAP-Targeted Radiopharmaceutical 155

7.6.7 Dec 18, 2024: BioView Presents Promising Results from Their Joint Liquid Biopsy Development Project 156

7.6.8 Dec 10, 2024: New Understanding of Aggressive Form of Breast Cancer Paves the Way for Tests and Treatments 157

7.6.9 Nov 06, 2024: Sonrai Accelerates Cancer Therapeutics Research with Advanced Analytics 157

7.6.10 Nov 02, 2024: New iPhone Device to Help Rule out Throat Cancer 158

7.6.11 Oct 06, 2024: New Government Tech Deals Boost the Business of Cancer Detection 159

7.6.12 Sep 30, 2024: New Genetic Testing Pathways Could Ensure Patients Get Personalised Treatments and Help to Catch More BRCA-Linked Cancer Cases 162

7.6.13 Sep 15, 2024: Imperial Startups Changing the World one Tech at a Time 163

7.6.14 Sep 14, 2024: SOPHiA GENETICS Presents Ground-Breaking Multimodal Research on AI-Driven Patient Stratification at ESMO 2024 165

7.6.15 Sep 09, 2024: Oxford Nanopore Announces Participation in the Progress Study, With Yemaachi Biotech 166

7.6.16 Aug 21, 2024: Breakthrough for Cancer Patients as a Network of Digitised NHS Pathology Departments Is Now Live in the North of England 167

7.6.17 Aug 19, 2024: Diaceutics Announces Launch of PMx 168

7.6.18 Jul 29, 2024: Groundbreaking Vine Robots with Magnetic Skin Could Transform Cancer Treatment 169

7.6.19 Jul 10, 2024: New Method of Measuring Tumour Infiltrating Lymphocytes Predicts Long Term Outcomes for a Type of early Breast Cancer 170

7.6.20 Jun 03, 2024: Mursla Bio Presents Breakthrough Liquid Biopsy Technology for Extracellular Vesicles in Cell Press 171

7.6.21 May 31, 2024: ASCO 2024: Prostate cancer spit test better for men with high genetic risk than standard blood test 171

7.7 Research And Development 173

7.7.1 Jul 24, 2024: Research Study Aims to Detect Lung Cancer Earlier via Simple Test 173

7.8 Strategy And Business Planning 173

7.8.1 May 28, 2025: Novellia Launches AI-Powered, Cross-Industry Research Initiative to Transform Breast Cancer Care 173

7.8.2 May 27, 2025: World-Leading Cancer Center, the Royal Marsden NHS Foundation Trust, Using AI To Push Boundaries of Cancer Research With Ntt Data and carpl.ai 174

7.8.3 May 15, 2025: N4 Pharma : Change of Registered Address 175

7.8.4 Apr 30, 2025: Inify Laboratories: Continued Strong Growth – Construction and Establishment in the UK 175

7.8.5 Apr 04, 2025: Google Cloud and Ai2 Announce Partnership With Cancer AI Alliance 175

7.8.6 Feb 27, 2025: Meditech Expanse Genomics and GenomOncology Integration Drives Targeted Cancer Treatments at Frederick Health 177

7.8.7 Dec 12, 2024: Tracer Biotechnologies Announces Multi-Year Project With AstraZeneca 178

7.8.8 Nov 26, 2024: Oxford Nanopore Technologies Announces New Collaboration With UK Biobank 178

7.8.9 Nov 05, 2024: UK to Create World-First ‘Early Warning System’ for Pandemics 179

7.8.10 Sep 23, 2024: Angle PLC Announces Exclusive Agreement for DNA NGS Panel 181

7.8.11 Sep 16, 2024: New Collaboration to Introduce Liquid Biopsy Testing for Lung Cancer 182

7.8.12 Aug 19, 2024: Diaceutics Announces Launch of PMx 182

7.8.13 Jun 11, 2024: Uk’s First Robotic Genome Testing Facility for Cancer Patients Launches 183

8 Appendix 185

8.1 Research Methodology 186

8.1.1 Coverage 186

8.1.2 Secondary Research 186

8.1.3 Primary Research 186

8.1.4 Market Modeling and Forecasting 187

8.1.5 Company Share Analysis 188

8.1.6 Benchmarking 189

8.2 GlobalData Consulting 190

8.3 Contact Us 190

8.4 Disclaimer 190

Table

Table 1: Oncology Market, United Kingdom, Revenue ($m), USD Constant, 2018-2033 17

Table 2: ALK Tests Market, United Kingdom, Revenue ($m), USD Constant, 2018-2033 20

Table 3: BCR-ABL Tests Market, United Kingdom, Revenue ($m), USD Constant, 2018-2033 22

Table 4: BRAF Tests Market, United Kingdom, Revenue ($m), USD Constant, 2018-2033 24

Table 5: BRCA Tests Market, United Kingdom, Revenue ($m), USD Constant, 2018-2033 26

Table 6: Colorectal Cancer Screening Tests Market, United Kingdom, Revenue ($m), USD Constant, 2018-2033 28

Table 7: EGFR Tests Market, United Kingdom, Revenue ($m), USD Constant, 2018-2033 30

Table 8: HER2 Tests Market, United Kingdom, Revenue ($m), USD Constant, 2018-2033 32

Table 9: KRAS Tests Market, United Kingdom, Revenue ($m), USD Constant, 2018-2033 34

Table 10: Oncology Market, United Kingdom, Volume (Units), 2018-2033 36

Table 11: ALK Tests Market, United Kingdom, Volume (Units), 2018-2033 39

Table 12: BCR-ABL Tests Market, United Kingdom, Volume (Units), 2018-2033 41

Table 13: BRAF Tests Market, United Kingdom, Volume (Units), 2018-2033 43

Table 14: BRCA Tests Market, United Kingdom, Volume (Units), 2018-2033 45

Table 15: Colorectal Cancer Screening Tests Market, United Kingdom, Volume (Units), 2018-2033 47

Table 16: EGFR Tests Market, United Kingdom, Volume (Units), 2018-2033 50

Table 17: HER2 Tests Market, United Kingdom, Volume (Units), 2018-2033 52

Table 18: KRAS Tests Market, United Kingdom, Volume (Units), 2018-2033 54

Table 19: Oncology Market, United Kingdom, Average Price ($), 2018-2033 55

Table 20: Oncology Market, United Kingdom, Company Share by Revenue ($m), 2024 60

Table 21: Oncology Market Pipeline Products 64

Table 22: EDX Medical Enters into Distribution Agreement with miRdetect 128

Table 23: Owkin Enters into Co-Development Agreement with AstraZeneca 129

Table 24: A. Menarini Diagnostics Enters into Distribution Agreement with Nucleix 131

Table 25: Vidac Pharma Holding Raises Approximately USD0.64 Million in Venture Financing 133

Table 26: Total Number of Primary Research Participants, In Vitro Diagnostics Market, by Country 187

Figures

Figure 1: Oncology Market, United Kingdom, Revenue ($m), USD Constant, 2018-2033 16

Figure 2: ALK Tests Market, United Kingdom, Revenue ($m), USD Constant, 2018-2033 19

Figure 3: BCR-ABL Tests Market, United Kingdom, Revenue ($m), USD Constant, 2018-2033 21

Figure 4: BRAF Tests Market, United Kingdom, Revenue ($m), USD Constant, 2018-2033 23

Figure 5: BRCA Tests Market, United Kingdom, Revenue ($m), USD Constant, 2018-2033 25

Figure 6: Colorectal Cancer Screening Tests Market, United Kingdom, Revenue ($m), USD Constant, 2018-2033 27

Figure 7: EGFR Tests Market, United Kingdom, Revenue ($m), USD Constant, 2018-2033 29

Figure 8: HER2 Tests Market, United Kingdom, Revenue ($m), USD Constant, 2018-2033 31

Figure 9: KRAS Tests Market, United Kingdom, Revenue ($m), USD Constant, 2018-2033 33

Figure 10: Oncology Market, United Kingdom, Volume (Units), 2018-2033 35

Figure 11: ALK Tests Market, United Kingdom, Volume (Units), 2018-2033 38

Figure 12: BCR-ABL Tests Market, United Kingdom, Volume (Units), 2018-2033 40

Figure 13: BRAF Tests Market, United Kingdom, Volume (Units), 2018-2033 42

Figure 14: BRCA Tests Market, United Kingdom, Volume (Units), 2018-2033 44

Figure 15: Colorectal Cancer Screening Tests Market, United Kingdom, Volume (Units), 2018-2033 46

Figure 16: EGFR Tests Market, United Kingdom, Volume (Units), 2018-2033 49

Figure 17: HER2 Tests Market, United Kingdom, Volume (Units), 2018-2033 51

Figure 18: KRAS Tests Market, United Kingdom, Volume (Units), 2018-2033 53

Figure 19: Oncology Market, United Kingdom, Company Share (%), 2024 59

United Kingdom (UK) Oncology Market Outlook to 2033: Colorectal Cancer Screening Tests, EGFR Tests, KRAS Tests and Others standard reports

Currency USD

Single User

$4,995

Can be used by individual purchaser only

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS

Related reports

View more In Vitro Diagnostics reports

Medical Devices

New

Global M&A Deals in H1 2026 - Top Themes by…

Medical Devices

New

Medical Devices M&A Deals H1 2026 - Top Themes: Strategic…

Medical Devices

New

AI-designed Materials: Market Trends and Innovations

Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at United Kingdom (UK) Oncology Market Outlook to 2033: Colorectal Cancer Screening Tests, EGFR Tests, KRAS Tests and Others in real time.

Access a live United Kingdom (UK) Oncology Market Outlook to 2033: Colorectal Cancer Screening Tests, EGFR Tests, KRAS Tests and Others dashboard for 12 months, with up-to-the-minute insights.
Fuel your decision making with real-time deal coverage and media activity.
Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.

Tell me more

Reports

Reports by Sector

Report Type

United Kingdom (UK) Oncology Market Outlook to 2033: Colorectal Cancer Screening Tests, EGFR Tests, KRAS Tests and Others

Scope

Reasons to Buy

Table of Contents

Table

Figures

Undecided about purchasing this report?

Get in touch to find out about multi-purchase discounts

Related reports